Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Upcoming investor conferences and the anticipated October 2026 topline results for the RAP-219 Phase 2 bipolar mania trial are the primary catalysts for the stock.
Management is scheduled to participate in a fireside chat at the Cantor Global Healthcare Conference in New York City. This event provides an opportunity for the company to discuss its clinical pipeline, including RAP-219, which may influence investor sentiment.
Rapport Therapeutics Press ReleaseManagement will participate in a virtual fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. The discussion is expected to focus on the company's precision neuroscience platform and clinical progress.
Rapport Therapeutics Press ReleaseThe company has previously stated that topline results for its Phase 2 trial of RAP-219 in bipolar mania are expected in October 2026. While this falls slightly outside the immediate two-week window, the proximity of the date makes it a significant ongoing catalyst for market expectations.
Rapport Therapeutics Press Release